Ankara Yildirim Beyazit University, Faculty of Medicine, Department of Nuclear Medicine, Ankara, Turkey.
Hell J Nucl Med. 2020 Jan-Apr;23(1):21-26. doi: 10.1967/s002449912002. Epub 2020 Mar 31.
Primary hyperparathyroidism (PHPT) is a common endocrine disease that is caused by a single adenoma in most of the cases. Surgical management is the mainstay and definitive treatment for parathyroid adenoma (PA). Minimally invasive surgical techniques are as effective as bilateral neck exploration with a lower risk of complications and better cosmetic results in patients with solitary PA. Accurate preoperative localization with imaging modalities is paramount for determining patients candidate for minimally invasive surgery. In this study we aimed to evaluate the diagnostic performance of technetium-99m-methoxyisobutylisonitrile ( Tc-MIBI) planar scintigraphy (PS), single photon emission tomography/computed tomography (SPET/CT) and ultrasonography (US) in patients with PHPT.
Fifty-eight patients with biochemical evidence of PHPT who underwent pre-operative imaging with parathyroid scintigraphy and US for detection and localization of PA and proceeded to surgery were included in the study. All patients underwent dual phase Tc-sesta MIBI parathyroid scintigraphy (early and delayed planar images and delayed SPET/CT). Data analysis was performed to evaluate the sensitivity, specificity, diagnostic accuracy and PPV of planar images, SPET/CT and US alone and combined US and SPET/CT. Histopathology was used as gold standard.
Sensitivity, specificity, PPV and diagnostic accuracy for detection of PA, 80,4%, 42,8%, 91,1% and 75,8% for PS; 80,4%, 57,7%, 91,1% and 77,5% for delayed SPET/CT; 88,2%, 85,7%, 97,8% and 87,9% for US and 94,1%, 71,4%, 96% and 91,3% for SPET/CT+US. Combined US and SPET/CT has been shown to increase sensitivity and diagnostic accuracy. The overall sensitivity of PS and SPET/CT didn't vary however additional information which is helpful for planning minimally invasive surgery gained from tomographic images.
The combined use of US and SPET/CT has incremental value in accurately localizing PA over either technique alone. In the preoperative assessment of patients with PHPT combination of imaging methods allows selection of patients who would be suitable for minimally invasive surgery.
原发性甲状旁腺功能亢进症(PHPT)是一种常见的内分泌疾病,在大多数情况下由单个腺瘤引起。手术治疗是甲状旁腺瘤(PA)的主要和确定性治疗方法。微创外科技术与双侧颈部探查一样有效,并发症风险较低,美容效果更好,适用于单发 PA 患者。准确的术前影像学定位对于确定微创外科手术的患者至关重要。在这项研究中,我们旨在评估 99mTc-甲氧基异丁基异腈(Tc-MIBI)平面闪烁显像(PS)、单光子发射断层扫描/计算机断层扫描(SPET/CT)和超声(US)在 PHPT 患者中的诊断性能。
58 例生化证实 PHPT 患者接受甲状旁腺闪烁显像和 US 术前成像,以检测和定位 PA,并进行手术。所有患者均行双时相 Tc-sesta MIBI 甲状旁腺闪烁显像(早期和延迟平面图像及延迟 SPET/CT)。对平面图像、SPET/CT 和 US 单独及联合 US 和 SPET/CT 的敏感性、特异性、诊断准确性和阳性预测值(PPV)进行数据分析。组织病理学作为金标准。
PA 的检测敏感性、特异性、PPV 和诊断准确性分别为 80.4%、42.8%、91.1%和 75.8%(PS);80.4%、57.7%、91.1%和 77.5%(延迟 SPET/CT);88.2%、85.7%、97.8%和 87.9%(US);94.1%、71.4%、96%和 91.3%(SPET/CT+US)。联合 US 和 SPET/CT 可提高敏感性和诊断准确性。PS 和 SPET/CT 的总体敏感性无差异,但从断层图像中获得了有助于微创外科计划的额外信息。
US 和 SPET/CT 的联合使用在准确定位 PA 方面具有增量价值,优于任何单一技术。在 PHPT 患者的术前评估中,联合使用成像方法可以选择适合微创外科手术的患者。